Skip to main content

Catalyst Calendar

Scope

Wed, Sep 9, 2026

1 updates
PYXS
7:00 AM

Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)

MICVO demonstrated rapid and deep responses, with a 36% confirmed objective response rate (cORR) and 94% disease control rate (DCR), with clinical activity observed across HPV status and prior-treatment subgroups Substantial survival outcomes include median progression-free survival (mPFS) of 6.2

Trial Results • Phase 1Updated data release and webcast Wed, Sep 9, 2026, 7:30 AM ETpyxisoncology.com

Tue, Sep 8, 2026

2 updates
PYXS
4:01 PM

Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)

Event to be webcast live on September 9, 2026 at 7:30 a.m. ET BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it will host a live webcast on

Results Call • Phase 1Results call Wed, Sep 9, 2026, 7:30 AM ETpyxisoncology.com

Tue, Sep 1, 2026

1 updates
PYXS
7:30 AM

Pyxis Oncology to Participate in Upcoming Investor Conferences

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Tom Civik, Interim Chief Executive Officer and Director of Pyxis Oncology, will participate in

pyxisoncology.com

Thu, Aug 13, 2026

1 updates

Tue, Jun 30, 2026

1 updates